HIV disease progression among women following seroconversion during a tenofovirbased HIV prevention trial

Simple item page
dc.contributor.authorRiddler, Sharon A.
dc.contributor.authorHusnik, Marla
dc.contributor.authorGita, Ramjee
dc.contributor.authorAnamika, Premrajh
dc.contributor.authorOnini Tutshana, Bomkazi
dc.contributor.authorArendevi, Pather
dc.contributor.authorSiva, Samantha
dc.contributor.authorJeenarain, Nitesha
dc.contributor.authorNair, Gonasagrie
dc.contributor.authorSelepe, Pearl
dc.contributor.authorKabwigu, Samuel
dc.contributor.authorPalanee-Phillips, Thesla
dc.contributor.authorPanchia, Ravindre
dc.contributor.authorMhlanga, Felix
dc.contributor.authorLisa, Levy
dc.contributor.authorLivant, Edward
dc.contributor.authorPatterson, Karen
dc.contributor.authorElharrar, Vanessa
dc.contributor.authorBalkus, Jennifer
dc.date.accessioned2022-08-05T16:48:12Z
dc.date.available2022-08-05T16:48:12Z
dc.date.issued2017
dc.description.abstractLittle is known regarding HIV disease outcomes among individuals who become infected with HIV while receiving antiretroviral medications for prevention. We compared HIV disease parameters among women who seroconverted while receiving tenofovir-containing oral or vaginal pre-exposure prophylaxis (PrEP) to placebo. Methods Participants with HIV seroconversion in a randomized placebo-controlled trial of oral tenofovir, oral tenofovir/emtricitabine, and vaginal tenofovir gel (MTN-003) were followed in a longitudinal cohort study (MTN-015). The effect of oral and vaginal tenofovir-containing PrEP on HIV disease progression was compared to placebo using linear mixed effects and Cox proportional hazard models, as appropriate. Additional analyses were performed to compare the outcomes among participants with detectable tenofovir or emtricitabine in plasma at the first quarterly visit in MTN-003. Results A total of 224 participants were included in the analysis; 93% from South Africa and 94% clade C virus. No differences in HIV RNA at steady state or the trajectory over 12 months were observed for each active arm compared to placebo; tenofovir gel recipients had higher CD4+ T cell counts (722 vs 596 cells/mm3; p = 0.02) at 90 days after estimated HIV seroconversion and higher average rates of change over 12 months compared to placebo (-181 vs -92 cells/mm3 per year; p = 0.08). With a median follow-up of 31 months, no significant differences were observed for time to CD4+ T cell count 350 cells/mm3, or the composite endpoint of CD4+ T cells 350 cells/mm3, initiation of antiretroviral therapy or death for each active arm compared to placebo. Additionally, there were no significant differences in the HIV RNA or CD4+ T cell counts at baseline, the change to month 12, or any disease progression outcomes among participants with oral drug detected and no oral drug detected compared to placebo. Conclusions No clinically significant differences in HIV seroconversion outcomes were observed among women randomized to tenofovir-containing oral or vaginal PrEP regimens, however low overall adherence limits the generalizability of these findings.en_US
dc.identifier.citationRiddler SA, Husnik M, Ramjee G, Premrajh A, Tutshana BO, Pather A, et al. (2017) HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS ONE 12(6): e0178594. https://doi.org/10.1371/journal.pone.0178594en_US
dc.identifier.urihttps://doi.org/10.1371/journal.pone.0178594
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/4260
dc.language.isoenen_US
dc.publisherPLoS ONEen_US
dc.subjectHIV diseaseen_US
dc.subjectWomenen_US
dc.subjectSeroconversionen_US
dc.subjectTenofovirbaseden_US
dc.titleHIV disease progression among women following seroconversion during a tenofovirbased HIV prevention trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
HIV disease progression among women.pdf
Size:
3.52 MB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences